Jadenu and Vonjo drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Jadenu (deferasirox) and Vonjo (pacritinib citrate). Common drug interactions include acute myelomonocytic leukaemia among females.
The phase IV clinical study analyzes what interactions people have when they take Jadenu and Vonjo. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.
What is Jadenu?
Jadenu has active ingredients of deferasirox. eHealthMe is studying from 4,176 Jadenu users. Check the latest studies of Jadenu.
What is Vonjo?
Vonjo has active ingredients of pacritinib citrate. eHealthMe is studying from 1,939 Vonjo users. Check the latest studies of Vonjo.
11 people who take Jadenu and Vonjo together, and have interactions are studied.
What are the common drug interactions of Jadenu and Vonjo, by gender? *:
female:
- Acute myelomonocytic leukaemia (cancer of the blood-forming organs)
- Diarrhoea
- Dysphagia (a condition in which swallowing is difficult or painful)
- Fatigue (feeling of tiredness)
- Haemoglobin decreased
- Malaise (a feeling of general discomfort or uneasiness)
male:
n/a
What are the common drug interactions of Jadenu and Vonjo, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
- Acute myelomonocytic leukaemia (cancer of the blood-forming organs)
- Diarrhoea
- Dysphagia (a condition in which swallowing is difficult or painful)
- Fatigue (feeling of tiredness)
- Haemoglobin decreased
- Malaise (a feeling of general discomfort or uneasiness)
60+:
n/a
What are the existing conditions these people have? *
- Acute Myelomonocytic Leukaemia (cancer of the blood-forming organs): 4 people, 36.36%
- Primary Myelofibrosis (primary disorder of the bone marrow): 2 people, 18.18%
- Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 18.18%
* Approximation only. Some reports may have incomplete information.
Do you take Jadenu and Vonjo?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Jadenu and Vonjo:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Jadenu:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Vonjo:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Jadenu and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Vonjo and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on deferasirox and pacritinib citrate (the active ingredients of Jadenu and Vonjo, respectively), and Jadenu and Vonjo (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Epidiolex cause Agitation? - a second ago
- Could Retin-A cause Constipation? - 2 seconds ago
- Could Plaquenil cause Wound Secretion? - 2 seconds ago
- Drug interactions of Procardia Xl and Propulsid - 6 seconds ago
- Bone Pain and Hypoaesthesia - 17 seconds ago
- Could Ranitidine cause Back Pain? - 19 seconds ago
- Bipolar I Disorder and Blood Albumin Decreased - 26 seconds ago
- Could Morphine cause Gouty Arthritis? - 31 seconds ago
- Drug interactions of Neulasta and Zocor - 38 seconds ago
- Drug interactions of Combivent Respimat and Benadryl - 44 seconds ago